Market Overview:
The global abdominal aortic aneurysm drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of abdominal aortic aneurysms, rising awareness about early diagnosis and treatment options, and technological advancements in the field of medical devices. Based on type, the global abdominal aortic aneurysm drug market is segmented into BSN-908, canakinumab, CT-2009, ticagrelor, and others. BSN-908 is expected to be the fastest growing segment during the forecast period due to its high efficacy and safety profile. Based on application, the global abdominal aortic aneurysm drug market is segmented into hospital pharmacies, clinic pharmacies, and others (including mail order pharmacies). The hospital pharmacy segment is expected to dominate this market during the forecast period owing to rising demand for these drugs from hospitals across regions.
Product Definition:
An abdominal aortic aneurysm (AAA) is a localized enlargement of the abdominal aorta, usually caused by weakening of the vessel wall. An AAA can cause pain and other symptoms if it ruptures.
BSN-908:
BSN-908 is a novel injectable aneurysm repair drug that was recently approved by the FDA. It’s a biologic response modifier designed to treat abdominal aortic aneurysms, which are bulging blood vessels in the abdominal wall and can rupture and cause bleeding at any time.
Canakinumab:
Canakinumab (AKA Canakinumab vedotin) is a humanized monoclonal antibody designed for the treatment of Crohn's disease. It was approved by the U.S. FDA in 2007 and has been used off-label to treat abdominal aortic aneurysm since 2010, when it was first introduced in the U.S., and 2011 in Europe, Japan, Australia & New Zealand (EJANZ).
Application Insights:
Based on application, the global abdominal aortic aneurysm drug market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to factors such as high prevalence of risk factors such as smoking and hypertension which increase the risk of developing an abdominal aortic aneurysm. In addition, increasing awareness about early diagnosis is also expected to drive growth over the forecast period.
The others segment includes surgical treatment performed outside hospitals or medical centers including open surgery and endovascular procedures.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure, high adoption rate of innovative drugs, and favorable reimbursement policies are some factors responsible for its large share. In addition, a rise in the prevalence of AAA is also expected to contribute towards its large share over the forecast period. According to data published by National Center for Health Statistics (NCHS), around 6 million people were diagnosed with an abdominal aortic aneurysm (AAA) between 2000 and 2013 while 1 million people above 40 years old were affected during this period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to increasing geriatric population and rising incidences of cardiovascular diseases such as stroke and heart failure which are majorly caused by AAA rupture or atherosclerosis that has leds to aneurysm formation in them.
Growth Factors:
- Increasing incidence of abdominal aortic aneurysm (AAA) due to aging population
- Growing demand for minimally invasive surgeries for AAA treatment
- Rising awareness about the symptoms and risk factors of AAA
- Technological advancements in diagnosis and treatment of AAA
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Abdominal Aortic Aneurysm Drug Market Research Report
By Type
BSN-908, Canakinumab, CT-2009, Ticagrelor, Others
By Application
Hospital, Clinic, Others
By Companies
AstraZeneca Plc, Carolus Therapeutics, Inc., Novartis AG, Vida Therapeutics Inc., AstraZeneca Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Abdominal Aortic Aneurysm Drug Market Report Segments:
The global Abdominal Aortic Aneurysm Drug market is segmented on the basis of:
Types
BSN-908, Canakinumab, CT-2009, Ticagrelor, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca Plc
- Carolus Therapeutics, Inc.
- Novartis AG
- Vida Therapeutics Inc.
- AstraZeneca Plc
Highlights of The Abdominal Aortic Aneurysm Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BSN-908
- Canakinumab
- CT-2009
- Ticagrelor
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Abdominal Aortic Aneurysm Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Abdominal aortic aneurysm (AAA) is a life-threatening condition in which the wall of the abdominal aorta weakens and bulges. This can cause blood to flow into the abdominal cavity, leading to death if not treated quickly.
Some of the key players operating in the abdominal aortic aneurysm drug market are AstraZeneca Plc, Carolus Therapeutics, Inc., Novartis AG, Vida Therapeutics Inc., AstraZeneca Plc.
The abdominal aortic aneurysm drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Abdominal Aortic Aneurysm Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Abdominal Aortic Aneurysm Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Abdominal Aortic Aneurysm Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Abdominal Aortic Aneurysm Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Abdominal Aortic Aneurysm Drug Market Size & Forecast, 2020-2028
4.5.1 Abdominal Aortic Aneurysm Drug Market Size and Y-o-Y Growth
4.5.2 Abdominal Aortic Aneurysm Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 BSN-908
5.2.2 Canakinumab
5.2.3 CT-2009
5.2.4 Ticagrelor
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Abdominal Aortic Aneurysm Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Abdominal Aortic Aneurysm Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 BSN-908
9.6.2 Canakinumab
9.6.3 CT-2009
9.6.4 Ticagrelor
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 BSN-908
10.6.2 Canakinumab
10.6.3 CT-2009
10.6.4 Ticagrelor
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 BSN-908
11.6.2 Canakinumab
11.6.3 CT-2009
11.6.4 Ticagrelor
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 BSN-908
12.6.2 Canakinumab
12.6.3 CT-2009
12.6.4 Ticagrelor
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 BSN-908
13.6.2 Canakinumab
13.6.3 CT-2009
13.6.4 Ticagrelor
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Abdominal Aortic Aneurysm Drug Market: Competitive Dashboard
14.2 Global Abdominal Aortic Aneurysm Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca Plc
14.3.2 Carolus Therapeutics, Inc.
14.3.3 Novartis AG
14.3.4 Vida Therapeutics Inc.
14.3.5 AstraZeneca Plc
